BRIEF—BeiGene to offer Brukinsa access in poorer countries

The non-profit Max Foundation, China-headquartered BeiGene and the BeiGene Foundation, a non-profit charitable foundation, today announced a collaboration to provide access to Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years.

This collaboration advances each organization’s focus on patient access by combining Max’s expertise and infrastructure with a donated product from BeiGene, and a grant from the BeiGene Foundation.

“We are thrilled to partner with BeiGene to help people living with CLL in low- and middle-income countries have access to Brukinsa,” said Pat Garcia-Gonzalez, chief executive of Max.

“This collaboration marks the first time patients with CLL will have access to treatment through Max. We commend BeiGene for joining ourHumanitarian Partnership for Access to Cancer Treatments (Humanitarian PACT) the same year Brukinsa received its US approval in CLL, demonstrating a powerful commitment to health equity for patients regardless of where they live,” she added.